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Abstract
BACKGROUND—Post-endovascular aortic aneurysm repair (EVAR) endoleaks and the need for 
reintervention are challenging. Additional endovascular treatment is advised for type Ia endoleaks 
detected on post-EVAR completion angiogram. This study analyzed management and late 
outcomes of these endoleaks.
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STUDY DESIGN—This was a retrospective review of prospectively collected data from EVAR 
patients during a 10-year period. All post-EVAR type Ia endoleaks on completion angiogram were 
identified (group A) and their early (30-day) and late outcomes were compared with outcomes of 
patients without endoleaks (group B). Kaplan-Meier analysis was used for survival analysis, sac 
expansion, late type Ia endoleak, and reintervention.
RESULTS—Seventy-one of 565 (12.6%) patients had immediate post-EVAR type Ia endoleak. 
Early intervention (proximal aortic cuffs and/or stenting) was used in 56 of 71 (79%) in group A 
vs 31 of 494 (6%) in group B (p < 0.0001). Late type Ia endoleak was noted in 9 patients (13%) in 
group A at a mean follow-up of 28 months vs 10 patients (2%) in group B at a mean follow-up of 
32 months (p < 0.0001). Late sac expansion and reintervention rates were 9% and 10% for group 
A vs 5% and 3% for group B (p = 0.2698 and p = 0.0198), respectively. Freedom rates from late 
type Ia endoleaks at 1, 3, and 5 years for group A were 88%, 85%, and 80% vs 98%, 98%, and 
96% for group B (p < 0.001); and for late intervention, were 94%, 92%, and 77% for group A, and 
99%, 97%, and 95% for group B (p = 0.007), respectively. Survival rates were similar.
CONCLUSIONS—Immediate post-EVAR type Ia endoleaks are associated with higher rates of 
early interventions, late endoleaks and reintervention, which will necessitate strict post-EVAR 
surveillance.
After endovascular aortic aneurysm repair (EVAR), patients may experience various 
complications, including endoleaks, device migration, graft deterioration/fractures, or 
aneurysm expansion that may require reintervention. Type I endoleak is defined as continued 
flow into the aneurysmal sac at the proximal attachment sites of the endograft to the native 
aorta or at the iliac artery wall distally, and is generally referred to as type Ia and type Ib 
endoleaks, respectively.1 These attachment site endoleaks have been demonstrated on post-
EVAR angiography in approximately 7% of patients.2 They usually prompt immediate 
treatment using proximal and/or distal extender modules, percutaneous transluminal 
angioplasty/stenting, or coil embolization.3,4 Also, an estimated 10% of patients who 
undergo EVAR may develop type I endoleaks at some time during follow-up.5
Failure to exclude abdominal aortic aneurysms (AAA) from continued perfusion (endoleak) 
and sac pressurization remains a serious challenge for EVAR.6–9 Additional endovascular 
therapy is generally advised for type Ia endoleaks detected on post-EVAR completion 
angiograms. Few studies have discussed the significance and management of these type Ia 
endoleaks. This analyzed the incidence, management, and late outcomes of these endoleaks.
METHODS
This is a retrospective review of prospectively collected data on 565 patients who underwent 
elective endovascular infrarenal aortic aneurysm repair (EVAR) at our medical center during 
a 10-year period. The devices used included AneuRx, Talent, and Endurant (Medtronic 
Corporation); Excluder (WL Gore and Associates); Zenith (Cook Corporation); and 
Powerlink (Endologix). Patients who lacked good quality preoperative CT scanning were 
excluded.
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All procedures were performed under general or epidural anesthesia using a modern imaging 
system (General Electric Medical). Patients were advised to participate in postoperative 
surveillance protocol, which included CT angiography (CTA) or color duplex ultrasound 
within 30 days of the procedure, and if normal (no evidence of endoleak or other 
abnormalities), a color duplex ultrasound was repeated at 6 months, 12 months, and every 12 
months thereafter. A CTA was obtained only if there was evidence of sac enlargement and/or 
endoleak by color duplex ultrasound.
Demographic and clinical characteristics of these patients were analyzed. All intraoperative 
data, including the presence of type Ia endoleaks at post-EVAR completion angiography and 
their treatment, 30-day postoperative adverse events, and late events were analyzed. This 
study was approved by the Institutional Review Board of Charleston Area Medical Center/
West Virginia University and informed consent was not required.
Definitions and primary endpoints
Every effort was made to follow the recommendations of the Ad Hoc Committee of the 
Stent Graft Standardized Reporting Practice in Vascular Surgery.10 Endoleak was 
determined using CT scanning if extravasation of contrast between the prosthesis and the 
aneurysm wall was noted or by color duplex ultrasound where the color flow and Doppler 
spectral signal were outside the prosthesis, or both. If the duplex ultrasound and CT results 
differed, conventional contrast arteriography was done to confirm the endoleak. The term 
“early endoleak” was used for a leak detected intraoperatively on completion angiography or 
less than 30 days postoperatively, and a “late endoleak” was defined as a leak discovered 30 
days or more postoperatively. Significant AAA sac expansion was defined as an increase of 
≥5 mm in sac size (compared with preoperative sac size), and significant shrinkage was 
defined as a decrease of ≥5 mm from the preoperative size. The term “migration” was 
determined by measuring the distance from lowest renal artery and the most cephalad part of 
the stent graft based on CT images. Significant migration was referred to as displacement 
requiring secondary intervention or displacement of ≥10 mm from the previous study.
The primary endpoint included early 30-day perioperative outcomes: rate of early endoleak 
(specifically, proximal type Ia) and the rate of early intervention, including the use of 
proximal aortic neck cuffs or proximal aortic stents to seal proximal aortic endoleak. Late 
clinical outcomes included late type Ia endoleaks, aortic sac expansion, late reintervention to 
treat endoleak or other complications, stent migration, conversion to open repair, and late 
mortality (aneurysm-related deaths). All deaths were verified using the Social Security 
Death Index.
Statistical methods
Data were analyzed using SAS 9.1. Comparisons were performed between patients with 
type Ia endoleak at post-completion EVAR angiography (group A) vs patients without 
endoleak (group B), using contingency table analysis with a chi-square or Fisher’s exact test 
(categorical variables) and t-tests (continuous variables) to determine statistically significant 
differences. The Kaplan-Meier method was used to compare rates of freedom from late type 
AbuRahma et al. Page 3













Ia endoleak, late intervention, sac expansion, and survival for both groups. Comparisons 
were based on the log-rank test.
RESULTS
Five hundred sixty-five patients were analyzed, and 71 of these had type Ia endoleak 
(12.6%; group A) on immediate post-completion EVAR angiography; 494 patients had none 
(87.4%; group B). Demographic and clinical characteristics of these patients are summarized 
in Table 1. As noted, there were no significant differences between both groups except for 
age.
Early intervention
Early intervention (use of proximal aortic cuffs or proximal aortic Palmaz stenting) was 
done in 56 of 71 patients (79%) in group A, vs 31 of 494 patients (6%) in group B (p < 
0.0001). The early intervention in group A included 5 proximal aortic Palmaz stents, 45 
aortic cuff extensions, and 6 patients had both aortic cuff extensions and Palmaz stents. The 
15 remaining patients in group A, who had no early intervention, were either treated with 
percutaneous transluminal angioplasty of the proximal aortic attachment site alone or were 
believed to have minimal proximal type Ia endoleak, which did not justify early intervention. 
Thirty-one patients in group B had early intervention (proximal aortic cuffs and/or aortic 
stents) for type Ia endoleaks, which were detected on the postoperative CTA and/or color 
duplex ultrasound that was done within 30 days, but were not present on the immediate post-
completion angiograms.
Late clinical outcomes
Late type Ia endoleak was noted in 9 patients (13%) in group A at a mean follow-up of 28 
months vs 10 patients (2%) in group B at a mean follow-up of 32 months (p < 0.0001). Late 
sac expansion and reintervention rates were 9% and 10% for group A vs 5% and 3% for 
group B (p = 0.2698 and p = 0.0198), respectively (Table 2). As noted, there were significant 
differences between late type Ia endoleak and late intervention between groups A and B. All 
patients with late type Ia endoleaks (9 patients) in group A had initial early post-EVAR type 
Ia endoleaks on completion angiograms, in contrast to 10 of 31 with late type Ia endoleaks 
in group B, who had early interventions for early endoleaks.
Overall, 7 of 68 patients in group A had late intervention: 3 due to sac expansion and 4 due 
to late type Ia endoleak. It should be noted that 1 patient had both late type Ia endoleak and 
sac expansion. Three patients in group A had no late outcomes beyond 30 days. These late 
interventions included placing another proximal aortic cuff in 3 patients, an aortic unilateral 
device with a femorofemoral bypass graft in 1 patient, a fenestrated EVAR in 2 patients, and 
1 patient was transferred, based on his request, to Cleveland Clinic, where he underwent 
further repair. Overall, there were 10 of 68 (15%) late deaths in group A vs 45 of 458 (10%) 
in group B (p = 0.2197). None of these late deaths were related to AAA rupture.
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Kaplan-Meier analysis of late type Ia endoleak, late intervention, sac expansion, and 
survival
Freedom rates from late type Ia endoleaks at 1, 3, and 5 years for group A were significantly 
lower: 88%, 85%, and 80% vs 98%, 98%, and 96%, respectively, for group B (p < 0.001; 
Fig. 1); and for late intervention, 94%, 92%, and 77% for group A vs 99%, 97%, and 95% 
for group B (p = 0.007), respectively (Fig. 2). The freedom rates from sac expansion at 1, 3, 
and 5 years for group A were 97%, 86%, and 81%, vs 98%, 92%, and 87% for group B, 
respectively (p = 0.373; Fig. 3). Figure 4 summarizes survival rates for both groups, which 
were similar.
DISCUSSION
In the modern era, endovascular management has become the standard treatment for 
infrarenal AAA, with up to 70% of them repaired by endovascular stent graft placement in 
the United States.11 Although EVAR has demonstrated better short-term and mid-term 
outcomes than open AAA treatment,12,13 as well as comparable long-term survival,14 up to 
15% to 20% of patients require a secondary intervention.15 One of the most troubling 
reasons for a secondary intervention is an endoleak, which can account for up to roughly 
57% of all reinterventions.16 Of all types of endoleaks, a type I endoleak is the most 
worrisome, and traditional teaching mandates immediate repair of this type of endoleak.16,17 
A type Ia endoleak involves the proximal seal; a type Ib endoleak involves the distal seal.
A type Ia endoleak is commonly discovered with the completion angiogram demonstrating 
contrast extravasation into the aneurysm sac, originating at or near the proximal seal zone. 
Because of the potential deleterious effects of this leak that can occur if left untreated, a 
variety of intraoperative adjunctive measures can be performed, such as balloon angioplasty 
of the proximal attachment site, proximal device extension, deployment of a large bare metal 
stent, embolization, or placement of endovascular screws.18–20 Others have advocated the 
chimney technique and fenestrated extension.21,22
Buth and colleagues23 reported the results of data collected in the EUROSTAR database 
from 110 European centers, and they noted that type I and type III endoleaks were 
associated with an increased frequency of open conversion or risk of aneurysm rupture. They 
also reported that 15 patients experienced aneurysm rupture at a mean of 16 months 
postoperatively (range 3 to 36 months): 10 (3.4%) patients with types I/III endoleak and 5 
(0.25%) without endoleaks. The cumulative rate of AAA rupture in patients with endoleak 
was 4% at 2 years and was significantly higher than in patients without endoleak (0.7%; p = 
0.0001). They believed that these endoleaks need to be treated without delay by 
endovascular means or by open repair.
In another study, Antoniou and associates24 conducted a systematic review and meta-
analysis of late rupture of AAAs after a previous EVAR and reported that 15 ruptures 
occurred after 16,974 EVAR procedures in 8 of the case series, with an incidence of 0.9%. 
The mean time to rupture was 37 months, and the predominant reasons for rupture were type 
I and III endoleaks. Of patients who underwent treatment, 61% had open surgery. They 
concluded that graft-related endoleaks appeared to be the predominant cause of late 
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aneurysm rupture. Antonopoulos and coworkers25 also reported on 22 patients with ruptured 
AAAs after previous EVAR, who presented to 7 referral hospitals in Greece; type Ia 
endoleak and endograft migration were identified in 72.7% and 50%, respectively. They 
concluded that type I endoleak and endograft migration were most frequently observed, and 
compliance to follow-up was low.
Recent studies now challenge the standard dogma of immediate treatment of type I 
endoleaks, in particular, type Ia endoleaks, claiming that spontaneous resolution with 
conservation management is possible without subsequent intervention. Tan and colleagues14 
evaluated more than 2,400 EVARs from the Vascular Study Group of New England database 
from 2003 to 2012, and they compared the outcomes of patients who had type I endoleaks at 
the completion of the procedure with those who did not. Eighty-eight (3.3%) of these 
patients had a type I endoleak at completion, and after a 1-year follow-up period, 90% of 
them had resolution of the endoleak without the need for any additional endovascular or 
open intervention.14
Risk factors identified for the initial type I endoleak included an age greater than 70 years, 
female sex, unplanned intraoperative graft extension, and a larger main body graft diameter 
requirement. Factors that were not independently associated with an intraoperative type I 
endoleak included maximum aneurysm size, smoking, and grafts with suprarenal fixation, 
all of which have been related to type I endoleaks in other publications.2,26,27 However, due 
to limitations inherent in the database analyzed, this study could not evaluate patients who 
had type I endoleaks treated successfully, and more importantly, could not differentiate 
between type Ia and Ib endoleaks. One could argue the natural history of spontaneous 
closure of a type Ib endoleak, or the durability of an intervention to correct the type Ib 
endoleak may be significantly different than that of a type Ia endoleak.28
In another recent study by Millen and associates,29 94% of patients with type Ia endoleaks 
found on completion arteriography after standard EVAR had endoleaks that resolved 
spontaneously. The initial completion arteriogram identified 44 of 209 patients with type Ia 
endoleaks, with 33 patients (75%) having a persistent endoleak even after intraoperative 
adjunctive procedures were performed, which included repeat balloon angioplasty, aortic 
cuff extension, and Palmaz stent (Cordis) placement.29 Eleven patients had successful 
treatment of the type Ia endoleak during the initial EVAR procedure, and there was no 
evidence of recurrent endoleak in these patients during a median follow-up of 27 months. 
For those 33 patients with persistent type Ia endoleaks, in spite of attempts at repair during 
the initial EVAR procedure, 31 showed spontaneous resolution of the endoleak on the first 
surveillance evaluation using CTA, resulting in a 94% spontaneous resolution.29
Other studies have reported similar results. In an evaluation of 15 patients, Bastos and 
colleagues30 identified 14 patients who had spontaneous type Ia endoleak closures, with 1 
patient ultimately developing a recurrent type Ia endoleak years later, and 1 patient with an 
unconfirmed recurrent endoleak. Kim and coworkers18 evaluated 86 patients undergoing 
EVAR and found spontaneous closure of type Ia endoleaks in 7 of 10 patients, although the 
median follow-up period was only 14 months.
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Venermo and coauthors31 reported that among 400 patients who were treated with EVAR at 
a single institution, 21 patients (5.3%) with large aneurysms (≥5.5 cm) had imaging 
evidence of type Ia endoleaks that persisted beyond 10 months, despite secondary 
endovascular treatment. They compared these patients with 24 untreated AAA patients. 
During follow-up, the rate of aneurysm enlargement was significantly lower in patients with 
type Ia endoleaks (0.19 cm/year) than in untreated AAA patients (0.54 cm/year; p = 0.03). 
One patient (4.8%) with a persisting type Ia endoleak and 2-cm aneurysm enlargement (0.8 
cm/year) had aneurysm rupture after 2.5 years, while 12 (50%) of the 24 untreated AAAs 
ruptured (p = 0.001). They concluded that EVAR may reduce the risk of rupture and 
aneurysm-related death despite the presence of a persisting type Ia endoleak.
In our study, 565 standard infrarenal EVARs were analyzed. Seventy-one patients had a type 
Ia endoleak identified during the initial EVAR procedure on completion angiography (group 
A); 494 patients demonstrated no evidence of type Ia endoleak on arteriography, again 
assessed at the initial EVAR procedure (group B). Of those 71 patients with endoleaks, 56 
underwent early interventions at the initial EVAR procedure, with placement of Palmaz 
stents in 5, aortic extension cuffs in 45, and a combination of both a Palmaz stent and an 
aortic cuff in 6 patients. Fifteen patients did not have any significant interventions other than 
standard compliant balloon inflation at the proximal seal zone; endoleaks discovered in these 
patients were deemed “minimal”, and the decision was made to forego more aggressive 
measures in favor of conservation and close re-evaluation. During further follow-up, 9 
patients continued to demonstrate “late” type Ia endoleaks persisting more than 30 days after 
the initial procedure. Of these 9 patients, 7 underwent late interventions: 3 patients had 
additional aortic cuff extensions, 1 patient underwent a combined aortounilimb placement 
along with a femoral-femoral bypass, and 2 patients underwent complex fenestrated graft 
repair. One patient chose transfer to another facility.
In group B, 494 patients did not demonstrate a type Ia endoleak on completion arteriography 
during the initial procedure. However, 31 patients ultimately had a type Ia endoleak 
discovered within 30 days of the original procedure (6%) using color duplex ultrasound 
and/or CTA; all of which underwent an early intervention for treatment. Despite these 
interventions, “late” type Ia endoleaks were discovered in 10 of these patients.
Comparing the 2 groups, group A had a significantly higher rate of early intervention (79% 
vs 6%), development of a late type Ia endoleak (13% vs 2%), and need for late intervention 
(10% vs 3%). Late sac expansion rates were also somewhat higher in group A (9% vs 5%). 
There was also a distinct disadvantage for group A with regard to freedom rates from type Ia 
endoleaks at 1, 3, and 5 years (88%, 85%, and 80% vs 98%, 98%, and 96%, respectively), as 
well as freedom rates for late intervention (94%, 92%, and 77% vs 99%, 97%, and 95%, 
respectively).
Our results are somewhat similar to those of Sampaio and associates,28 who sought to 
determine the frequency and nature of intraoperative endoleaks and their impact on 
postoperative endoleak-related events. An endoleak was observed in 126 of 241 patients 
(52.3%). Type I endoleaks were observed in 63 (26.1%) cases: 35 type Ia and 31 type Ib (3 
patients had both). These endoleaks were treated with angioplasty, additional cuff 
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placement, or stenting in 59 (89.4%). They also reported that patients with a type I or II 
intraoperative endoleak were more often likely to have an endoleak at 1.5 years (31.4% vs 
21.6%; p = 0.018). Reinterventions were needed more often in patients with intraoperative 
type I endoleak (10% vs 4%; p = 0.003). Patients with intraoperative endoleaks 
demonstrated a trend toward less post-operative aneurysm sac diameter reduction at 2 years 
(43.8% vs 74.5%; p = 0.104). They concluded that the presence of a type I or type II 
endoleak during EVAR significantly increases the likelihood of a postoperative endoleak and 
should prompt a high degree of suspicion during late follow-up.
So based on our study, identification of a type Ia endoleak at the time of the initial procedure 
signifies a more troublesome situation, one that requires diligent monitoring postoperatively 
and a higher likelihood of recurrent type Ia endoleak. The need for subsequent intervention 
is less if no endoleak is discovered on completion arteriography after standard EVAR, but 
we would, nevertheless, recommend some degree of continued postoperative surveillance to 
ensure these leaks do not develop at a later time.
There are a few limitations of our study. The main one lies with its retrospective design, 
which carries all of the inherent bias associated with patient selection and device selection 
(which is at the discretion of the physician). We were also limited to the data that were 
routinely collected and stored in electronic medical records. In addition, there was no 
uniformity in the method of surveillance.
CONCLUSIONS
Immediate post-EVAR type Ia endoleak is associated with higher rates of early 
interventions, late endoleaks, and intervention, which will necessitate stricter post-EVAR 
surveillance.
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Freedom from late type Ia endoleak for groups A and B.
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Freedom from late intervention for groups A and B.
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Freedom from late sac expansion for groups A and B.
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Survival analysis for groups A and B.
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Table 1
Demographic and Clinical Characteristics
Characteristic Group A (total n = 71) Group B (total n = 494) p Value
Mean age, y, (range)    75.7 (48–96)        72.9 (45–101) 0.0138
Age, y, n (%)
 <75 30 (42) 280 (57) 0.0224
 ≥75 41 (58) 214 (43)
 ≥80 31 (44) 134 (27)
Sex, n (%)
 Male 53 (75) 408 (83) 0.1063
 Female 18 (25)   86 (17)
Hypertension, n (%) 60 (85) 428 (87) 0.6243
COPD, n (%) 23 (32) 161 (33) 0.9736
Tobacco use, n (%) 48 (68) 308 (62) 0.3909
Congestive heart failure, n (%) 11 (15)   63 (13) 0.5223
Stroke/transient ischemic attack, n (%) 11 (15) 45 (9) 0.0923
Atrial fibrillation, n (%) 12 (17)   59 (12) 0.2386
Coronary artery disease, n (%) 36 (51) 294 (60) 0.159
Carotid disease, n (%) 6 (8)   56 (11) 0.467
Peripheral vascular disease, n (%)   7 (10)   56 (11) 0.7116
Home oxygen, n (%)   7 (10) 27 (5) 0.176
Diabetes, n (%) 13 (18) 106 (21) 0.543
Hyperlipidemia, n (%) 44 (62) 324 (66) 0.55
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Table 2
Early and Late Endoleak and Intervention
Endoleak/intervention Group A (total n = 71)* Group B (total n = 494) p Value
Early intervention, n (%) 56 (79) 31 (6) <0.0001
Late type Ia endoleak, n (%)     9 (13)* 10 (2) <0.0001
Sac expansion, n (%)   6 (9)* 25 (5) 0.2698
Late intervention, n (%)     7 (10)* 16 (3) 0.0198
*
Three patients had no late outcome (beyond 30 days).
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